Biotech Essentials

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 14.07.2021.

#AML
#collab
#biotech
#MultipleSclerosis
#metabolomics

Startups

@GVteam shared
On Jul 13, 2021
RT @schenkein: Congrats to David Liu @davidrliu and Keith Gottesdiener and everyone on the Prime team on the official launch of Prime Medicine. The @GVteam is excited to be part of this journey to make important medicines for patients. https://t.co/e2xpCYRPtp
Open
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

/PRNewswire/ -- Prime Medicine™, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, today announced its launch with...

@ForbesTech shared
On Jul 13, 2021
This gene editing startup raised $315 million for a next generation Crispr tool to cure rare diseases https://t.co/7BkzJ45ZQ3 by @katiedjennings
Open
This Gene Editing Startup Raised $315 Million For A Next Generation Crispr Tool To Cure Rare Diseases

This Gene Editing Startup Raised $315 Million For A Next Generation Crispr Tool To Cure Rare Diseases

Prime Medicine’s ‘search and replace’ platform could potentially correct up to 89% of the known mutations that can cause genetic disease.

@big4bio shared
On Jul 13, 2021
.@JNJNews ($JNJ) teamed up with @VorBioPharma ($VOR) to study one of its bispecific antibodies combined with technology designed to improve tolerability. J&J aims to create a treatment for acute myeloid leukemia. #AML #biotech #collab Learn more here: https://t.co/TmIUI4Kyg6
Open
J&J, Vor ally to assess bispecific and stem cell therapy in AML

J&J, Vor ally to assess bispecific and stem cell therapy in AML

Johnson & Johnson has teamed up with Vor Biopharma to study one of its bispecific antibodies in combination with technology designed to improve tolerability. 

@LifeSciVC shared
On Jul 12, 2021
RT @atlasventure: We are thrilled to welcome Jodie Morrison to our team today! https://t.co/MrmaPZ48s5 https://t.co/i8dYTiT4ce
Open
Atlas Venture Welcomes Jodie Morrison as Venture Partner

Atlas Venture Welcomes Jodie Morrison as Venture Partner

Jodie Morrison joins Atlas Venture as venture partner to build transformative biotech companies.

@BentheFidler shared
On Jul 13, 2021
Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs https://t.co/jgj0dJLI3P $BIIB $SNY $RHHBY $MKKGY #MultipleSclerosis
Open
Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs

Biogen chases rivals with another bet on emerging class of multiple sclerosis drugs

A deal with Innocare gives Biogen a second therapy for MS that targets a protein called BTK, an approach several other competing drugmakers are pursuing, too.

@om shared
On Jul 9, 2021
.@danprimack notes many all time records in 1H 2021 in techlandia: * VC dollars invested: $288bn * VC dollars invested in US startups: $140bn * Startups sold: $232bn * 410 companies went public (Thanks SPACs) * 5,248 PE/VC funds looking for $900bn https://t.co/ElgaAvArhG
Open
Axios Pro Rata

Axios Pro Rata

— Felix Salmon, Axios • Clearco, a San Francisco-based provider of non-dilutive, revenue-based financing to startups, raised $215 million in new Series C funding from SoftBank …

@MALifeSciences shared
On Jul 9, 2021
RT @AaronJDy: 14 great projects getting funding from @MALifeSciences including $1.8 million grant for new #metabolomics facility @DanaFarber https://t.co/7Crkrjh0h4 Dr. Nika Danial to lead new center that'll support research across the institute and nearby institutions https://t.co/S34Bi87Yxz
Open
Massachusetts Life Sciences Center funding to support a Metabolomics Facility at Dana-Farber

Massachusetts Life Sciences Center funding to support a Metabolomics Facility at Dana-Farber

The Massachusetts Life Sciences Center is awarding Dana-Farber Cancer Institute a $1.82 million grant titled, Mass Spectrometry Metabolomics Solutions for Highly Scalable Integrated OMics: ...

@FierceBiotech shared
On Jul 12, 2021
The therapeutic focus moves Novo into competition with Alnylam. Having won approval for Onpattro in hereditary ATTR amyloidosis, Alnylam is studying the RNAi drug in patients with cardiomyopathy https://t.co/pTYxdQT2sC
Open
Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion

Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program. The deal will see Novo pay $100 million in upfront and near-term fees for worldwide rights to the ...